Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents
Denise M. Wolf, Laura van ‘t Veer, Lajos Pusztai(Yale University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Laura Sit(Memorial Sloan Kettering Cancer Center), Jean‐Philippe Coppé(University of California, San Francisco), Lamorna A. Brown Swigart(University of California, San Francisco), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Mark Jesus M. Magbanua(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Rosalyn W. Sayaman(University of California, San Francisco), Angela DeMichele(University of Pennsylvania), Gillian L. Hirst(University of California, San Francisco), I-SPY Investigators(Quantum Leap Healthcare Collaborative)
Cited by 0
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
|Unknown|2008|4.1k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k